bluuebunny/crossref_metadata_2025 huggingface dataset:
Identifying ADHD-Related Abnormal Functional Connectivity with a Graph Convolutional Neural Network
Authors: Hu Yilin , Ran Junling , Qiao Rui , Xu Jiayang , Tan Congming , Hu Liangliang , Tian Yin
Published: May 2024

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that is characterized by inattention, hyperactivity, and impulsivity. The neural mechanisms underlying ADHD remain inadequately understood, and current approaches do not well link neural networks and attention networks within brain networks. Our objective is to investigate the neural mechanisms related to attention and explore neuroimaging biological tags that can be generalized within the attention networks. In this paper, we utilized resting-state functional magnetic resonance imaging data to examine the differential functional connectivity network between ADHD and typically developing individuals. We employed a graph convolutional neural network model to identify individuals with ADHD. After classification, we visualized brain regions with significant contributions to the classification results. Our results suggest that the frontal, temporal, parietal, and cerebellar regions are likely the primary areas of dysfunction in individuals with ADHD. We also explored the relationship between regions of interest and attention networks, as well as the connection between crucial nodes and the distribution of positively and negatively correlated connections. This analysis allowed us to pinpoint the most discriminative brain regions, including the right orbitofrontal gyrus, the left rectus gyrus and bilateral insula, the right inferior temporal gyrus and bilateral transverse temporal gyrus in the temporal region, and the lingual gyrus of the occipital lobe, multiple regions of the basal ganglia and the upper cerebellum. These regions are primarily involved in the attention executive control network and the attention orientation network. Dysfunction in the functional connectivity of these regions may contribute to the underlying causes of ADHD.
Enhancing Quality Characteristics of Cold-Pressed Sesame Oil with Ethanolic Extract of Quince (Cydonia oblonga), alongside with Exploring the Interaction of Trans Fatty Acids with Key Proinflammatory Cytokines via Molecular Docking
Authors: Mirzaei Hamed , Salehi Khayyam , Jafari Ameneh , Chaleshtori Reza Sharafati
Published: May 2024

Currently, there is a growing trend of replacing synthetic antioxidants with natural alternatives to prevent the oxidation of edible oils. Herein, we assessed the phenolic compounds and antioxidant properties of ethanolic extracts that are obtained from Cydonia oblonga (SQ). Furthermore, we incorporated SQ at two different concentrations (1% and 2%) into cold-pressed sesame oil, storing it for 30 days under ambient conditions. We then assessed the peroxide value (PV), acid value (AV), oxidative stability using the Rancimat apparatus, and the fatty acid (FA) composition. Additionally, we performed the molecular docking analyses to explore the interaction between trans fatty acids (TFAs; C18:1 and C18:2) and key proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). The total phenol, flavonoid content, and antioxidant activity of SQ were found to be 95.33±5.03 mg GAE/g, 343.67±16.44 mg QE/g, and 465.67±5.51 mmol Fe2+/g, respectively. The presence of SQ exhibited a significant impact on reducing PV and AV when compared to the control group. Furthermore, the addition of SQ resulted in a significant increase in the induction period (IP) compared to the control. The predominant FAs in the samples were 18:2n-6, 18:1n-9, 16:0, and 18:0, respectively. The levels of TFAs in all samples at 30 days were higher than those at 0 day. TNF-α and IL-6 showed a higher binding affinity for the trans-C18:1 ligand, with a docking score of -6.81 and -5.82, respectively, compared to the trans-C18:2 ligand. In this context, SQ can be proposed as a natural antioxidant to enhance the oxidative stability of sesame oil. Additionally, the binding preferences and specific interactions of TFAs with these proinflammatory cytokines indicate their potential role in modulating inflammation.
Supplementary Figure S7 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Authors: Yan Linlin , Wu Mingming , Wang Tianyu , Yuan Hui , Zhang Xiao , Zhang Huafeng , Li Tao , Pandey Vijay , Han Xinghua , Lobie Peter E. , Zhu Tao
Published: May 2024

Supplementary Figure S7 shows that MIF is associated with immunosuppressive Tumor microenvironment.
Supplementary Figure S5 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Authors: Yan Linlin , Wu Mingming , Wang Tianyu , Yuan Hui , Zhang Xiao , Zhang Huafeng , Li Tao , Pandey Vijay , Han Xinghua , Lobie Peter E. , Zhu Tao
Published: May 2024

Supplementary Figure S5 shows that MIF promotes cancer cell proliferation, migration and invasion.
Supplementary Figure S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion
Authors: Yan Linlin , Wu Mingming , Wang Tianyu , Yuan Hui , Zhang Xiao , Zhang Huafeng , Li Tao , Pandey Vijay , Han Xinghua , Lobie Peter E. , Zhu Tao
Published: May 2024

Supplementary Figure S1 shows that CoCl2 CM enhances breast cancer glycolysis.
Supplementary Table S2 from Severity of Complications and Duration of Type 2 Diabetes and the Risk of Cancer: A Population-Based Study
Authors: Hu Yu-Wen , Yeh Chiu-Mei , Liu Chia-Jen , Chen Tzeng-Ji , Huang Nicole , Chou Yiing-Jenq
Published: May 2024

Supplementary Table S2: Specific cancer types and their corresponding ICD-9 and ICD-10 codes
Supplementary Table S9 from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

Supplementary Table S9 shows Significantly altered lipids derived from stage stratified analysis.
Supplementary Table S5 from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

Supplementary Table S5 shows UHPLC-MS system suitability.
Table S4 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Authors: Andersen Høgni H. , Bojesen Stig E. , Johansen Julia S. , Ejlertsen Bent , Berg Tobias , Tuxen Malgorzata , Madsen Kasper , Danø Hella , Flyger Henrik , Jensen Maj-Britt , Nielsen Dorte L.
Published: May 2024

Standardized mortality ratio by categorized CRP
Table S2 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Authors: Andersen Høgni H. , Bojesen Stig E. , Johansen Julia S. , Ejlertsen Bent , Berg Tobias , Tuxen Malgorzata , Madsen Kasper , Danø Hella , Flyger Henrik , Jensen Maj-Britt , Nielsen Dorte L.
Published: May 2024

Recurrence according to BMI groups
Supplementary Table S14 from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

Supplementary Table S14 shows Machine learning performance for discriminant 17-lipid panel.
Figure S3 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Authors: Andersen Høgni H. , Bojesen Stig E. , Johansen Julia S. , Ejlertsen Bent , Berg Tobias , Tuxen Malgorzata , Madsen Kasper , Danø Hella , Flyger Henrik , Jensen Maj-Britt , Nielsen Dorte L.
Published: May 2024

Continuous CRP and recurrence
Supplementary Table S12 from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

Supplementary Table S12 shows Classification performance of the 10-lipid panel for early-stage OC vs. benign conditions (without cervical cancer samples).
Figure S1 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Authors: Andersen Høgni H. , Bojesen Stig E. , Johansen Julia S. , Ejlertsen Bent , Berg Tobias , Tuxen Malgorzata , Madsen Kasper , Danø Hella , Flyger Henrik , Jensen Maj-Britt , Nielsen Dorte L.
Published: May 2024

Flowchart
Supplementary Figure S10 from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

Supplementary Figure S10 shows Average ganglioside abundance in OC and non-OC serum samples.
Supplementary Table S1 from Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status
Authors: Van Alsten Sarah C. , Dunn Matthew R. , Hamilton Alina M. , Ivory Joannie M. , Gao Xiaohua , Kirk Erin L. , Nsonwu-Farley Joseph S. , Carey Lisa A. , Abdou Yara , Reeder-Hayes Katherine E. , Roberson Mya L. , Wheeler Stephanie B. , Emerson Marc A. , Hyslop Terry , Troester Melissa A.
Published: May 2024

Supplementary Table S1 shows the concordance between clinical assay results for OncotypeDx and in-house research based version.
Supplementary Figure S1 from Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status
Authors: Van Alsten Sarah C. , Dunn Matthew R. , Hamilton Alina M. , Ivory Joannie M. , Gao Xiaohua , Kirk Erin L. , Nsonwu-Farley Joseph S. , Carey Lisa A. , Abdou Yara , Reeder-Hayes Katherine E. , Roberson Mya L. , Wheeler Stephanie B. , Emerson Marc A. , Hyslop Terry , Troester Melissa A.
Published: May 2024

Supplementary Figure S1 depicts geographic differences in OncotypeDx testing across the state of North Carolina. It also shows the magnitude of racial disparities by region within the state.
Supplementary Table 4 from Association between Airport Ultrafine Particles and Lung Cancer Risk: The Multiethnic Cohort Study
Authors: Bookstein Arthur , Po Justine , Tseng Chiuchen , Larson Timothy V. , Yang Juan , Park Sung-shim L. , Wu Jun , Shariff-Marco Salma , Inamdar Pushkar P. , Ihenacho Ugonna , Setiawan Veronica W. , DeRouen Mindy C. , Le Marchand Loïc , Stram Daniel O. , Samet Jonathan , Ritz Beate , Fruin Scott , Wu Anna H. , Cheng Iona
Published: May 2024

Supplementary Table 4 shows an analysis of co-pollutants (NO2, PM10, PM2.5) and UFP Associations by Lung Cancer Histologies among California MEC Participants from 1993-2013.
Supplementary Table 1 from Association between Airport Ultrafine Particles and Lung Cancer Risk: The Multiethnic Cohort Study
Authors: Bookstein Arthur , Po Justine , Tseng Chiuchen , Larson Timothy V. , Yang Juan , Park Sung-shim L. , Wu Jun , Shariff-Marco Salma , Inamdar Pushkar P. , Ihenacho Ugonna , Setiawan Veronica W. , DeRouen Mindy C. , Le Marchand Loïc , Stram Daniel O. , Samet Jonathan , Ritz Beate , Fruin Scott , Wu Anna H. , Cheng Iona
Published: May 2024

Supplementary Table 1 shows an overview of the study characteristics of California Multiethnic Cohort (MEC) Participants at Baseline by Race and Ethnicity between 1993-1996.
Supplementary Figure 4 from Diffsig: Associating Risk Factors with Mutational Signatures
Authors: Park Ji-Eun , Smith Markia A. , Van Alsten Sarah C. , Walens Andrea , Wu Di , Hoadley Katherine A. , Troester Melissa A. , Love Michael I.
Published: May 2024

This figure shows the simulation results on the 80% credible interval coverages and absolute errors of the estimates per simulation
Supplementary Figure 2 from Diffsig: Associating Risk Factors with Mutational Signatures
Authors: Park Ji-Eun , Smith Markia A. , Van Alsten Sarah C. , Walens Andrea , Wu Di , Hoadley Katherine A. , Troester Melissa A. , Love Michael I.
Published: May 2024

This figure shows the detected HiLDA Signatures on TCGA Breast Cancer Data
Data from Severity of Complications and Duration of Type 2 Diabetes and the Risk of Cancer: A Population-Based Study
Authors: Hu Yu-Wen , Yeh Chiu-Mei , Liu Chia-Jen , Chen Tzeng-Ji , Huang Nicole , Chou Yiing-Jenq
Published: May 2024

AbstractBackground:
The literature on the association between diabetes severity and cancer risk is limited and inconclusive. The study aimed to evaluate the association between the adapted Diabetes Complications Severity Index (aDCSI) and the duration of type 2 diabetes and cancer risk.
Methods:
Patients ages 20 years or older with newly diagnosed type 2 diabetes between January 1, 2007, and December 31, 2011, were identified from Taiwan National Health Insurance claims data. Standardized incidence ratios (SIR) were calculated to compare cancer incidence in people with diabetes with that in the general population. Poisson regression was used to examine whether SIRs differed by age, sex, aDSCI, and duration of diabetes.
Results:
A total of 756,547 patients were included, with a median follow-up of 8.8 years. Excluding the first year after diagnosis, the SIR for overall cancer was 1.18 [95% confidence interval (CI) 1.17–1.19]. Higher aDCSI was associated with increased SIRs for overall [SIR ratio 1.03 (1.02–1.03) per point increase], head and neck (1.03; 1.01–1.04), liver (1.04; 1.03–1.05), pancreas (1.03; 1.00–1.05), kidney (1.13; 1.10–1.15), and leukemia (1.09; 1.06–1.13). There was no association between aDCSI and colorectal, extrahepatic biliary tract, uterus and thyroid cancer, and a negative association with breast cancer (0.97; 0.95–0.98). Type 2 diabetes duration was associated with increased SIRs for overall [1.01 (1.00–1.02) per year increase], head and neck (1.03; 1.01–1.05), and liver cancer (1.04; 1.02–1.05).
Conclusions:
The heterogeneity in the association between diabetes severity and diabetes-related cancers suggests diverse underlying connections.
Impact:
Adopting distinct approaches in further research and prevention strategies for different kinds of diabetes-related cancers is important.
Data from Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Authors: Sah Samyukta , Bifarin Olatomiwa O. , Moore Samuel G. , Gaul David A. , Chung Hyewon , Kwon Sun Young , Cho Hanbyoul , Cho Chi-Heum , Kim Jae-Hoon , Kim Jaeyeon , Fernández Facundo M.
Published: May 2024

AbstractBackground:
Distinguishing ovarian cancer from other gynecological malignancies is crucial for patient survival yet hindered by non-specific symptoms and limited understanding of ovarian cancer pathogenesis. Accumulating evidence suggests a link between ovarian cancer and deregulated lipid metabolism. Most studies have small sample sizes, especially for early-stage cases, and lack racial/ethnic diversity, necessitating more inclusive research for improved ovarian cancer diagnosis and prevention.
Methods:
Here, we profiled the serum lipidome of 208 ovarian cancer, including 93 early-stage patients with ovarian cancer and 117 nonovarian cancer (other gynecological malignancies) patients of Korean descent. Serum samples were analyzed with a high-coverage liquid chromatography high-resolution mass spectrometry platform, and lipidome alterations were investigated via statistical and machine learning (ML) approaches.
Results:
We found that lipidome alterations unique to ovarian cancer were present in Korean women as early as when the cancer is localized, and those changes increase in magnitude as the diseases progresses. Analysis of relative lipid abundances revealed specific patterns for various lipid classes, with most classes showing decreased abundance in ovarian cancer in comparison with other gynecological diseases. ML methods selected a panel of 17 lipids that discriminated ovarian cancer from nonovarian cancer cases with an AUC value of 0.85 for an independent test set.
Conclusions:
This study provides a systemic analysis of lipidome alterations in human ovarian cancer, specifically in Korean women.
Impact:
Here, we show the potential of circulating lipids in distinguishing ovarian cancer from nonovarian cancer conditions.
Overcoming Delays in the Progress against Cancer: Identifying Tobacco Use among Cancer Patients Enrolled in Clinical Trials
Authors: Warren Graham W. , Presant Cary A.
Published: May 2024

Though smoking causes adverse cancer treatment outcomes and smoking cessation can improve survival, prior literature demonstrates deficits in collecting tobacco use information in clinical trials. Results by Streck and colleagues represent a thorough structured assessment of tobacco use and alternative tobacco product use in patients enrolled in cooperative group trials. Among patients with predominantly non–tobacco related cancers, observations demonstrate that approximately 27% of patients reported using one or more forms of tobacco use after diagnosis. Alternative tobacco use was reported by many patients, including patterns of dual use. Results demonstrate the feasibility of collecting comprehensive structured tobacco use information, and further support the need to address tobacco and cessation even among patients with non–tobacco related cancers.

See related article by Streck and colleagues, Cancer Epidemiol Biomarkers Prev 2023;32:1552–57
Supplementary Figure S5 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Authors: Saito Shin , Kono Michihisa , Nguyen Hoang C.B. , Egloff Ann Marie , Messier Cameron , Lizotte Patrick , Paweletz Cloud , Adkins Douglas , Uppaluri Ravindra
Published: May 2024

Figure S5
A, B. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 tumors harvested on day 16 post tumor inoculation. Number of cells per tumor mg
are shown. (n=6 for esc1_Ctrl, n=8 for esc1_CCL5, representative data of two independent experiments.)
C. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (Left panel, n=12 for Ctrl, n=14 for
esc1_CCL5, pooled data from two independent experiments. Right panel, n=18 for Ctrl, n=20 for esc1_CCL5. Pooled data from three independent experiments.)
D, E. Flow cytometric analysis of MOC1esc1_Ctrl and MOC1esc1_CCL5 DLN harvested on day 16 post tumor inoculation. (n= 6 for Ctrl, n=8 for CCL5,
representative data of two independent experiments.)
F. Total cells (5*105cells/well) isolated from MOC1esc1_Ctrl or MOC1esc1_CCL5 DLNs were stimulated with indicated peptides for 48 hours and evaluated
by IFN-γ ELISA. PC; (positive control (PMA + ionomycin)), NC; negative control (no peptides). (Left panel, n=8. Right panel, n=3, representative data of
two independent experiments.)
G. Flow cytometric analysis of MOC2_Ctrl and MOC2_CCL5 tumors harvested on day 10 post tumor inoculation. (n=8.)
Supplementary Figure S3 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Authors: Saito Shin , Kono Michihisa , Nguyen Hoang C.B. , Egloff Ann Marie , Messier Cameron , Lizotte Patrick , Paweletz Cloud , Adkins Douglas , Uppaluri Ravindra
Published: May 2024

Figure S3
A. Representative flow cytometry results of isolated Xcr1+ cDC1s used for DC vaccine experiments.
B. Histogram of indicated marker expression gated on Xcr1+ cDC1s analyzed by flow cytometry. Xcr1+ cDCs were isolated and cultured
with (=activated) or without (=no stimulation) PolyI:C (20 μg/ml) for 4 hours before staining.
C, D. IFN-γ ELISA testing the ability of Xcr1+ DCs to activate CD8+ T cells. CD8+ cells isolated from OT-1 mouse splenocyte (OT1) were
co-cultured with Xcr1+ cDC1s (DC), with or without stimulation of ovalbumin short peptide (short), ovalbumin synthetic long peptide (SLP) in
Figure S3C and MOC1esc1-OVA (full length) cell lysate (MOC1esc1OVA) in Figure S3D. n=2-3.
E, F. Flow cytometric analysis of MOC1esc1 tumors (E) and DLNs (F) treated with intra-tumoral PBS or DC vaccine on days 1/4/7 post inoculation,
and harvested on day 14 post tumor inoculation. (n=8, representative data of two independent experiments.)
G. Tumor weight measured on last day of experiment in Figure 3E.
H. Photo of tumors harvested in experiment shown in Figure 3E
Supplementary Figure S1 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer
Authors: Saito Shin , Kono Michihisa , Nguyen Hoang C.B. , Egloff Ann Marie , Messier Cameron , Lizotte Patrick , Paweletz Cloud , Adkins Douglas , Uppaluri Ravindra
Published: May 2024

Figure S1
A. Xcr1+ DCs in DLNs of MOC1P-ova/MOC1esc1-ova harvested 10 days post inoculation were analyzed by flow cytometry. Total number of cells per
LN and number of cells per 10,000 CD45+ cells are shown. (n=5, representative data of two independent experiments.)
B. Representative gating strategies for Figure 1B, C.
Individual data and mean ± SD are plotted in Figure S1A. Data were analyzed using the Mann–Whitney U Test to generate two-tailed P values in Figure S1A
Supplementary Table 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Authors: Else Tobias , Jonasch Eric , Iliopoulos Othon , Beckermann Kathryn E. , Narayan Vivek , Maughan Benjamin L. , Oudard Stephane , Maranchie Jodi K. , Iversen Ane B. , Goldberg Cynthia M. , Fu Wei , Perini Rodolfo F. , Liu Yanfang , Linehan W. Marston , Srinivasan Ramaprasad
Published: May 2024

Supplementary Table 2. Patient-level summary of LGR by best overall response.
Table 1 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

Revised tumor classification for previously designated SCLC-Y lines.
Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Authors: Else Tobias , Jonasch Eric , Iliopoulos Othon , Beckermann Kathryn E. , Narayan Vivek , Maughan Benjamin L. , Oudard Stephane , Maranchie Jodi K. , Iversen Ane B. , Goldberg Cynthia M. , Fu Wei , Perini Rodolfo F. , Liu Yanfang , Linehan W. Marston , Srinivasan Ramaprasad
Published: May 2024

Supplementary Figure 2. Efficacy of belzutifan monotherapy for pancreatic neuroendocrine tumors. A, Kaplan-Meier curve of progression-free survival for pancreatic neuroendocrine tumors. B, Spider plot showing change from baseline over time in size of target pancreatic neuroendocrine tumors.
Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Authors: Sheth Sangini S. , Oh Ji Eun , Bellone Stefania , Siegel Eric R. , Greenman Michelle , Mutlu Levent , McNamara Blair , Pathy Shefali , Clark Mitchell , Azodi Masoud , Altwerger Gary , Andikyan Vaagn , Huang Gloria , Ratner Elena , Kim Daniel J. , Iwasaki Akiko , Levi Angelique W. , Buza Natalia , Hui Pei , Flaherty Sean , Schwartz Peter E. , Santin Alessandro D.
Published: May 2024

Representativeness of Study Participants
Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Authors: Sheth Sangini S. , Oh Ji Eun , Bellone Stefania , Siegel Eric R. , Greenman Michelle , Mutlu Levent , McNamara Blair , Pathy Shefali , Clark Mitchell , Azodi Masoud , Altwerger Gary , Andikyan Vaagn , Huang Gloria , Ratner Elena , Kim Daniel J. , Iwasaki Akiko , Levi Angelique W. , Buza Natalia , Hui Pei , Flaherty Sean , Schwartz Peter E. , Santin Alessandro D.
Published: May 2024

Study protocol
Supplementary Table S2 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

Immunohistochemistry scoring table.
Supplementary Figure S5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

SMARCA4-UT cluster validation.
Supplementary Figure S4 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

H&E and immunohistochemistry of cell line xenografts H661, H1581 and SBC5.
Supplementary Figure S4 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
Authors: Guarducci Cristina , Nardone Agostina , Russo Douglas , Nagy Zsuzsanna , Heraud Capucine , Grinshpun Albert , Zhang Qi , Freelander Allegra , Leventhal Mathew Joseph , Feit Avery , Cohen Feit Gabriella , Feiglin Ariel , Liu Weihan , Hermida-Prado Francisco , Kesten Nikolas , Ma Wen , De Angelis Carmine , Morlando Antonio , O'Donnell Madison , Naumenko Sergey , Huang Shixia , Nguyen Quang-Dé , Huang Ying , Malorni Luca , Bergholz Johann S. , Zhao Jean J. , Fraenkel Ernest , Lim Elgene , Schiff Rachel , Shapiro Geoffrey I. , Jeselsohn Rinath
Published: May 2024

Focal CNVs in PDX1526-Mut and PDX1415-WT and enriched transcription pathways between the two PDX models.
Figure 5 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

YAP1 is expressed in SMARCA4-UT primary samples. A, Unsupervised hierarchical clustering, based on a SCLC-specific YAP1 signature (n = 49 genes) identified by Pearsall and colleagues (10), was performed on SCCOHT and lung carcinoma samples [cell lines from the CCLE and bulk-RNA sequenced patient samples from Le Loarer and colleagues (24)]. Cell lines that cluster with the SMARCA4-UT samples are highlighted in the gray box. B, YAP1 IHC on SCLC-A/N/P and SMARCA4-mutant cell line xenografts. Scale bar = 100 μm. C, H&E, SMARCA4, and YAP1 IHC in primary SMARCA4-UT samples (n = 6) together with an SCLC patient sample. Scale bar = 100 μm.
Figure 3 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

Distinct immunophenotype of SMARCA4-mutant compared with SMARCA4-WT SCLC cell lines. Representative IHC images of SMARCA4, synaptophysin (SYN), CD56, TTF1, INSM1, and RB1 in SMARCA4-WT, NE-high SCLC cell line (H1092) compared with SMARCA4-mutant SCLC cell lines. Scale bar = 100 μm.
Figure 1 from Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Authors: Ng Jin , Cai Ling , Girard Luc , Prall Owen W.J. , Rajan Neeha , Khoo Christine , Batrouney Ahida , Byrne David J. , Boyd Danielle K. , Kersbergen Ariena J. , Christie Michael , Minna John D. , Burr Marian L. , Sutherland Kate D.
Published: May 2024

SMARCA4 mutations are enriched within SCLC-Y cell lines. A, Venn diagram showing co-occurring and subtype-specific mutations associated with each SCLC molecular subtype. Genetic mutations that are present in at least 50% of samples within each SCLC subtype based on Rudin and colleagues (2) were identified through cBioportal. There are 26 mutations exclusive to SCLC-Y cell lines (Supplementary Table S7). B, Of all 26 mutations identified, SMARCA4 mutations were present in six of eight SCLC-Y cell lines, together with TP53 mutations on an RB1 wild-type background. *, H157DM was previously annotated in CCLE as H1339. C, All cell lines in the CCLE (lung and nonlung cancer cell lines) that had complete proteomic and RNA-seq profiles were interrogated for the correlation between SMARCA4 protein and mRNA. There is a positive correlation (Pearson correlation = 0.53; P = 1.5e−27) between low SMARCA4 mRNA and loss of SMARCA4 protein. D, SCLC cell lines with SMARCA4 mutations have a significantly lower NE-score compared with wild-type (WT) SMARCA4 SCLC cell lines (Mann–Whitney test; **, P = 0.0068). SCLC cell lines in the CCLE were binned into SMARCA4 mutant and WT groups. NE scoring was performed using a previously published 50-gene transcriptomic signature (16).
Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
Authors: Cieniewicz Brandon , Oliveira Edson , Saxton Mike , Torabi Damoun , Bhatta Ankit , Kukutla Phanidhar , Arballo Alexander , Yang Zhuo , Yu Bi , Fate Maria , Ning Hongxiu , Corey Lawrence , Maiti Abhishek , Corey Daniel
Published: May 2024

Supplementary materials and methods, tables, and figures
Supplementary Figure S8 from Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites
Authors: Hou Yuzhu , Yang Kaiting , Wang Liangliang , Wang Jiaai , Huang Xiaona , Piffkó András , Luo Sean Z. , Yu Xinshuang , Rao Enyu , Martinez Carlos , Bugno Jason , Mack Matthias , Vokes Everett E. , Pitroda Sean P. , Chmura Steven J. , Weichselbaum Ralph R. , Liang Hua Laura
Published: May 2024

Supplementary Figure 8. Schematic models of hypothesis that local tumor irradiation can have
immune-stimulating and immune-suppressive effects locally and systemically
Supplementary Figure S7 from Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites
Authors: Hou Yuzhu , Yang Kaiting , Wang Liangliang , Wang Jiaai , Huang Xiaona , Piffkó András , Luo Sean Z. , Yu Xinshuang , Rao Enyu , Martinez Carlos , Bugno Jason , Mack Matthias , Vokes Everett E. , Pitroda Sean P. , Chmura Steven J. , Weichselbaum Ralph R. , Liang Hua Laura
Published: May 2024

Supplementary Figure 7. PD-L1 and MDSC blockade promoted an IR-induced abscopal effect.
Supplementary Table S5 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
Authors: Williams AnnaLynn M. , Liu Wei , Ehrhardt Matthew J. , Mirzaei Salehabadi Sedigheh , Panoskaltsis-Mortari Angela , Phillips Nicholas S. , Mulrooney Daniel A. , Flerlage Jamie E. , Yasui Yutaka , Srivastava Deokumar , Robison Leslie L. , Hudson Melissa M. , Ness Kirsten K. , Sabin Noah D. , Krull Kevin R.
Published: May 2024

Representativeness of Study Participants
Supplementary Table S3 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
Authors: Williams AnnaLynn M. , Liu Wei , Ehrhardt Matthew J. , Mirzaei Salehabadi Sedigheh , Panoskaltsis-Mortari Angela , Phillips Nicholas S. , Mulrooney Daniel A. , Flerlage Jamie E. , Yasui Yutaka , Srivastava Deokumar , Robison Leslie L. , Hudson Melissa M. , Ness Kirsten K. , Sabin Noah D. , Krull Kevin R.
Published: May 2024

Mean difference and 95%CI in neurocognitive z-scores among those in the third or second tertile of biomarker concentration compare to the first tertile. Models were adjusted for age, sex, race, body mass index, anti-inflammatory/steroid use, and recent infection
Supplementary Figure S2 from Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites
Authors: Hou Yuzhu , Yang Kaiting , Wang Liangliang , Wang Jiaai , Huang Xiaona , Piffkó András , Luo Sean Z. , Yu Xinshuang , Rao Enyu , Martinez Carlos , Bugno Jason , Mack Matthias , Vokes Everett E. , Pitroda Sean P. , Chmura Steven J. , Weichselbaum Ralph R. , Liang Hua Laura
Published: May 2024

Supplementary figure 2. Gene expression pathways are enriched for PD-L1 production and
leukocyte migration in lung of irradiated mice.
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Authors: Mariniello Annapaola , Nasti Tahseen H. , Chang Daniel Y. , Hashimoto Masao , Malik Sakshi , McManus Daniel T. , Lee Judong , McGuire Donald J. , Cardenas Maria A. , Umana Pablo , Nicolini Valeria , Antia Rustom , Saha Ananya , Buchwald Zachary , Kissick Hayden , Ghorani Ehsan , Novello Silvia , Sangiolo Dario , Scagliotti Giorgio V. , Ramalingam Suresh S. , Ahmed Rafi
Published: May 2024

(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Authors: Mariniello Annapaola , Nasti Tahseen H. , Chang Daniel Y. , Hashimoto Masao , Malik Sakshi , McManus Daniel T. , Lee Judong , McGuire Donald J. , Cardenas Maria A. , Umana Pablo , Nicolini Valeria , Antia Rustom , Saha Ananya , Buchwald Zachary , Kissick Hayden , Ghorani Ehsan , Novello Silvia , Sangiolo Dario , Scagliotti Giorgio V. , Ramalingam Suresh S. , Ahmed Rafi
Published: May 2024

(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
Supplementary Figure 4 from Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance
Authors: Liu Yang , Yan Wenbin , Hu Chaosu , Huang Xiaodong , Wang Kai , Qu Yuan , Chen Xuesong , Wu Runye , Zhang Ye , Zhang Jianghu , Luo Jingwei , Li Yexiong , Wang Jingbo , Yi Junlin
Published: May 2024

The impact of T stage on nodal drainage distance.
Supplementary Figure 1 from Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance
Authors: Liu Yang , Yan Wenbin , Hu Chaosu , Huang Xiaodong , Wang Kai , Qu Yuan , Chen Xuesong , Wu Runye , Zhang Ye , Zhang Jianghu , Luo Jingwei , Li Yexiong , Wang Jingbo , Yi Junlin
Published: May 2024

Diagram of the study patients identiﬁcation.
Supplementary Table S3 from Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC
Authors: Wu Christina , Pai Reetesh K. , Kosiorek Heidi , Banerjee Imon , Pfeiffer Ashlyn , Hagen Catherine E. , Hartley Christopher P. , Graham Rondell P. , Sonbol Mohamad B. , Bekaii-Saab Tanios , Xie Hao , Sinicrope Frank A. , Patel Bhavik , Westerling-Bui Thomas , Shivji Sameer , Conner James , Swallow Carol , Savage Paul , Cyr David P. , Kirsch Richard , Pai Rish K.
Published: May 2024

Supplementary Table S3. Carcinoembryonic antigen levels according to ASCO and QuantCRC-Integrated risk groups.
Supplementary Table S2 from Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC
Authors: Wu Christina , Pai Reetesh K. , Kosiorek Heidi , Banerjee Imon , Pfeiffer Ashlyn , Hagen Catherine E. , Hartley Christopher P. , Graham Rondell P. , Sonbol Mohamad B. , Bekaii-Saab Tanios , Xie Hao , Sinicrope Frank A. , Patel Bhavik , Westerling-Bui Thomas , Shivji Sameer , Conner James , Swallow Carol , Savage Paul , Cyr David P. , Kirsch Richard , Pai Rish K.
Published: May 2024

Supplementary Table S2. Concordance between ASCO and QuantCRC-Integrated risk groups
Supplementary Table S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Table S4. Baseline patient- and disease related characteristics.
Supplemental Table 8 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Table 8. RNAseq differential gene expression analysis summary
Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Figure S6. Clinical trajectories with 3 years of follow up.
Supplemental Table 5 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Table 5. Genes mutated in both MF and ET/PV/PrePMF cohorts
Supplementary Figure S5 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Figure S5. Stimulated cytokine response in patients with or without pre-treatment infections.
Supplementary Figure S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Figure S2. Changes in innate immune responses during acalabrutinib and combined ibrutinib+venetoclax by sub cohort.
Supplemental Table 1 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Table 1. Mi-Oncoseq gene list
Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Figure S1. Innate immune responses at baseline vs 2-3 cycles of BTKi.
Supplemental Figure 6 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Figure 6. Gene expression in Ras pathway mutant MF. Panel A shows the heatmap of differentially expressed genes in a comparison of mutant Ras pathway MF vs wild type Ras pathway. Nine upregulated genes were identified. Panel B shows the gene expression differences in a volcano plot. Panel C is the gene set enrichment analysis of CD34 enriched MF samples with and without Ras mutations. Ras pathway and PI3K pathway were upregulated in MF patients that harbor mutant Ras pathway genes.
Supplemental Figure 2 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Figure 2. Overall survival from Collection of sample. Survival differences were also analyzed from the time of collection of sample instead of time of diagnosis. Panel A shows survival difference between MF with 0-3 variants and >=4 variants. Panel B shows survival difference between MF patients harboring Ras pathway mutations and those not. Panel C shows the percent survival of patients with ASXL1 mutations in <=60 and >60 age groups as compared to patients without ASXL1 mutation in the same age brackets.
Supplemental Figure 1 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Figure 1. PCA and UMAP plots identifying the 14 outlier samples excluded from gene expression analysis. These plots summarize the identification of outliers in the RNAseq dataset using principal component analysis (PCA) and Uniform Manifold Approximation and Projection (UMAP). PCA plot and UMAP visually shows how separable the classes under consideration are with respect to the selected group of features.
Supplementary Video S6 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Video S6. Meso^CD19 CAR T cells on AsPC1
Supplementary Video S3 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Video S3. Meso^FAP CAR T cells on CAF
Supplementary Video S12 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Video S12. UTD T cells not on target
Supplementary Figure S8 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Figure S8. Target expression and individual analysis of patient-derived organoids (PDO) with matching CAFs.
Supplementary Table S1 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Authors: Anderson Thomas M. , Chang Bryan H. , Huang Alexander C. , Xu Xiaowei , Yoon Daniel , Shang Catherine G. , Mick Rosemarie , Schubert Erin , McGettigan Suzanne , Kreider Kristin , Xu Wei , Wherry E. John , Schuchter Lynn M. , Amaravadi Ravi K. , Mitchell Tara C. , Farwell Michael D.
Published: May 2024

Supplementary Table S1. Baseline patient and disease characteristics.